false

Nicholas Richardson, DO, MPH

An expert in hematology and oncology and a veteran of the FDA with almost nine years of experience, culminating as a Deputy Director for the Division of Hematologic Malignancies 2. Possesses a profound understanding of regulatory strategy, particularly in the development of CAR-T cell therapies, bispecifics and T-cell engagers. Spearheaded initiatives to develop novel endpoints in blood cancer such as minimal residual disease (MRD) in lymphoma and chronic lymphocytic leukemia (CLL.)

• Read: What the EMA–FDA AI Principles Really Mean for Clinical Development & Regulatory Affairs

  Clinical Trials - Regulatory

  What the EMA–FDA AI Principles Really Mean for Clinical Development & Regulatory Affairs

  Mar 13, ‘26 | 5 min read

  • 

  • John M.

    Nicholas R.

    Rosamund R.

  Discover

Loading...

You've reach the end Back to top